[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Saint Petersburg State University, Russia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":357},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,74,104,139,166,194,220,243,271,305,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100636333","implantation-of-an-adjustable-suburethral-sling-is-an-effective-treatment-method-for-patients-with-mixed-urinary-incontinence-of-moderate-to-severe-severity-after-which-the-severity-of-the-stress-and-urgency-components-is-reduced-100636333",false,"NCT07564323","Implantation of an Adjustable Suburethral Sling is an Effective Treatment Method for Patients With Mixed Urinary Incontinence of Moderate to Severe Severity, After Which the Severity of the Stress and Urgency Components is Reduced.","Optimizing the Management of Patients With Mixed Urinary Incontinence.","Inclusion Criteria:\n\n* Women over 18 years of age.\n* Mixed urinary incontinence (stress and urgency components, with the stress component being predominant or equal) of moderate to severe severity, confirmed by questionnaire data.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Isolated stress or urge urinary incontinence.\n* Contraindications to diagnosis and treatment.\n* Obstructive urination, large residual urine volume.\n* Chronic pelvic pain syndrome.\n* Pelvic organ prolapse (grade 2 or higher according to POP-Q).\n* History of any suburethral sling implantation.\n* History of surgical treatment for pelvic organ prolapse.\n* Pregnancy.","FEMALE","18 Years",{"count":19,"type":20},156,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this clinical study is to optimize treatment outcomes in patients with mixed forms of urinary incontinence by implanting an adjustable suburethral sling and to determine factors influencing treatment effectiveness. The main questions it aims to answer are:\n\n1. What is the effectiveness of an adjustable suburethral sling in patients with mixed urinary incontinence?\n2. How do preoperative medications and other factors affect the effectiveness of adjustable suburethral sling implantation?\n3. How does quality of life change in these patients after surgery? Participants will undergo implantation of an adjustable suburethral sling. Postoperatively, the effectiveness of the sling for mixed urinary incontinence will be assessed. Predictors of treatment effectiveness will also be identified.\n\nPatients will be examined 24 hours after surgery, 2 months later, and 1 year later.",[26],"Mixed Urinary Incontinence",[28],"mixed urinary incontinence, adjustable suburethral sling","NOT_YET_RECRUITING","2026-04-26",{"date":32,"type":33},"2026-05-04","ACTUAL",{"date":35,"type":20},"2026-04-24",{"date":37,"type":20},"2028-04-24",{"name":39,"class":40},"Saint Petersburg State University, Russia","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100602525","phase-4-sore-throat-after-open-neck-elective-surgery-100602525","NCT07124650","Sore Throat After Open Neck Elective Surgery","Effect of Hydrocortisone and Lidocaine on Endotracheal Tube for Sore Throat and Hoarseness After Thyroid\u002FParathyroid Surgery With Neuromonitoring: A Randomized Controlled Trial","STONES","Inclusion Criteria:\n\n* Patients scheduled for elective open surgery on the thyroid\u002Fparathyroid glands with intraoperative neuromonitoring.\n* Age ≥18 years.\n* Willing and able to provide voluntary informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Pregnancy (for women of childbearing potential).\n* Known allergy to hydrocortisone or lidocaine.\n* Refusal to participate in the study.","ALL",{"count":51,"type":20},764,[53],"PHASE4","This randomized clinical trial aims to evaluate the effectiveness of two medications-hydrocortisone ointment and lidocaine solution-applied to the endotracheal tube in reducing postoperative throat pain, hoarseness, and cough following thyroid or parathyroid surgery with neuromonitoring.\n\nA total of 764 adult patients undergoing elective neck surgery at Saint-Petersburg State University Hospital will be enrolled and randomly assigned to receive either a hydrocortisone-coated or lidocaine-coated endotracheal tube.\n\nOutcomes will be assessed upon awakening from anesthesia, at 24 hours, and again at 3 days postoperatively.\n\nThe findings may contribute to improving postoperative comfort and recovery for patients undergoing similar surgical procedures.",[56,57],"Postoperative Sore Throat, Cough, Hoarseness","Thyroid and Parathyroid Surgery",[59,60,61,62,63],"Hydrocortisone","Lidocaine","Endotracheal tube","Neuromonitoring","Randomized controlled trial","RECRUITING","2026-04-06",{"date":67,"type":33},"2026-04-13",{"date":69,"type":33},"2025-09-15",{"date":71,"type":20},"2027-05",{"name":39,"class":40},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100601887","phase-4-intrapleural-ropivacaine-infusion-in-cardiac-surgery-100601887","NCT07116343","Intrapleural Ropivacaine Infusion in Cardiac Surgery","Intrapleural Ropivacaine Infusion in Cardiac Surgery: Randomized Double-blind Controlled Study","IRICS","Inclusion Criteria:\n\n* Scheduled cardiac surgery using a standard median sternotomy.\n* Planned opening of the pleural cavities.\n* Age more than 18 years.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Contraindications for ropivacaine\n* Redo surgery",{"count":83,"type":20},116,[53],"For many patients, a primary source of postoperative pain following cardiac surgery is the presence of pleural drains, which the surgeon places at the end of the operation and maintains for 1 to 3 days. One promising method of pain management after cardiac surgery is interpleural analgesia, particularly when traditional analgesic methods, such as systemic opioids or epidural anesthesia, may be limited due to the risk of complications. Interpleural analgesia involves the introduction of local anesthetics directly into the pleural cavity through drainage tubes placed after cardiac surgery. This method targets pain receptors in the chest area, providing effective analgesia without significant systemic effects. Several clinical studies have confirmed the safety and efficacy of intrapleural administration of anesthetics after thoracic surgery. The aim of this randomised double-blind placebo controlled study is to test the hypothesis that, in patients after cardiac surgery, the quality of recovery from anesthesia with intrapleural use of ropivacaine is superior to that with a placebo.",[87,88,89],"Cardiac Surgery","Coronary Artery Disease","Valvular Diseases",[91,92,93,94],"cardiac surgery","quality of recovery","ropivacaine","postoperative analgesia","2026-03-06",{"date":97,"type":33},"2026-03-10",{"date":99,"type":33},"2025-10-22",{"date":101,"type":20},"2027-12-01",{"name":39,"class":40},2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":122,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100533194","ppg-vs-icg-in-gastrointestinal-resections-100533194","NCT06222645","PPG vs. ICG in Gastrointestinal Resections","Comparison Between Fluorescenceimaging With Photoplethysmography （PPG） and Indocyaningreen (ICG) for Tissue Perfusion in Gastrointestinal Resections","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years).\n* Scheduled to undergo an elective gastrointestinal resection requiring a primary gastro-intestinal or entero-enteric anastomosis.\n* Able to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to indocyanine green (ICG), iodine, or any component of the ICG formulation.\n* Severe hepatic impairment (e.g., Child-Pugh Class C).\n* Pregnancy or lactation.\n* Emergency surgery.\n* Inability to comply with the study protocol or follow-up schedule in the investigator's judgment.",{"count":112,"type":20},200,[23],"This randomized controlled trial compares a novel optical technique against the standard of care for assessing tissue perfusion in gastrointestinal surgery. Participants are randomized to receive either intraoperative imaging photoplethysmography (iPPG) or indocyanine green (ICG) fluorescence imaging. In the ICG group, the fluorescence data are comprehensively analyzed in two distinct ways: (1) Qualitative Assessment: real-time visual interpretation of the angiogram flow by the operating surgeon; and (2) Quantitative Assessment: software-based analysis of fluorescence kinetics (e.g., time-to-peak, maximum intensity) to generate objective perfusion parameters. The study aims to determine the agreement between the iPPG-based evaluations and both the qualitative and quantitative dimensions of the ICG standard.",[116,117,118,119,120,121],"Anastomosis","Perfusion","Postoperative Complications","Gastrointestinal Neoplasms","Gastric Cancer (GC)","Colorectal Cancer",[123,124,125,126,127,128,129],"Photoplethysmography","Indocyanine Green","Fluorescence Imaging","Anastomotic Leak","Gastrointestinal Surgery","Tissue Perfusion","Intraoperative Monitoring","2025-11-14",{"date":132,"type":33},"2025-11-18",{"date":134,"type":33},"2023-11-01",{"date":136,"type":20},"2026-05-31",{"name":39,"class":40},3,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":73},"100544877","phase-2-efficacy-of-pembrolizumab-and-lenvatinib-in-patients-with-anaplastic-thyroid-cancer-100544877","NCT06374602","Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer","Inclusion Criteria:\n\n* immunohistochemically verified anaplastic thyroid cancer that is not eligible to R0-R1 surgery;\n* age ≥ 18 years;\n* functional status of ECOG 0-2;\n* adequate function of internal organs and bone marrow;\n* the ability to give written informed consent.\n\nExclusion Criteria:\n\n* patients with a mutation in the BRAF V600 gene without previous targeted therapy with BRAF\u002FMEK inhibitors;\n* patients with clinically significant hemoptysis and bleeding (for example, from the gastrointestinal tract or tumor-associated bleeding);\n* tumor invasion into large vessels;\n* patients with open wounds and fistulas;\n* contraindications to taking any of the studied drugs;\n* patients with poor functional status (ECOG 3-4);\n* continuous use of immunosuppressive therapy;\n* prior therapy with investigational drugs;\n* pregnancy, breast-feeding",{"count":146,"type":20},20,[148],"PHASE2","This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.",[151],"Anaplastic Thyroid Cancer",[153,154,155,156,157],"Anaplastic thyroid cancer","Immunotherapy","Targeted therapy","Lenvatinib","Pembrolizumab","2025-08-29",{"date":160,"type":33},"2025-09-05",{"date":162,"type":33},"2024-03-25",{"date":164,"type":20},"2026-06-25",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":73},"100601101","carbon-suspension-vs-metallic-marker-for-axillary-lymph-node-marking-in-breast-cancer-after-neoadjuvant-therapy-100601101","NCT07106112","Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy","A Randomized Trial Comparing Carbon Suspension (Black Eye) and Metallic Markers (TWIRL ULTRACOR) for Localization of Metastatic Axillary Lymph Nodes Prior to Neoadjuvant Systemic Therapy in Breast Cancer Patients.","COMET","Inclusion Criteria:\n\n* Women ≥18 years.\n* Morphologically confirmed breast cancer (T1-3N1M0).\n* ECOG 0-1.\n* Indication for neoadjuvant therapy.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* No lymph node regression post-neoadjuvant therapy (persistent N1).\n* Distant metastasis progression.\n* Severe comorbidities (NYHA III-IV, COPD GOLD D, Child-Pugh C).",{"count":175,"type":20},110,[23],"This single-center, randomized study aims to compare the intraoperative detection rates of axillary lymph nodes marked with carbon suspension versus metallic markers in breast cancer patients (T1-3N1M0) before neoadjuvant therapy. Primary endpoint: frequency of marked lymph node identification during surgery. Secondary endpoints: time from marking to surgery and quality of life (EORTC QLQ-BR23).",[179],"Breast Cancer",[181,182,183,184,185],"Carbon suspension","Axillary lymph node marking","Neoadjuvant therapy","Targeted axillary dissection","Metallic marker","2025-08-02",{"date":188,"type":33},"2025-08-06",{"date":190,"type":33},"2025-05-15",{"date":192,"type":20},"2026-12-31",{"name":39,"class":40},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":73},"100567695","effect-of-kidney-replacement-therapy-with-polymethylmethacrylate-membranes-on-pruritus-related-quality-of-life-in-patients-receiving-maintenance-haemodialysis-100567695","NCT06671535","Effect of Kidney Replacement Therapy with Polymethylmethacrylate Membranes on Pruritus-related Quality of Life in Patients Receiving Maintenance Haemodialysis","Inclusion Criteria:\n\n* Diagnosis of CKD stage 5D, maintenance hemodialysis not less than 3 months prior screening;\n* Moderate-to-severe pruritis (WI-NRS score ≥ 4);\n* Adequate dialysis dose (spKt\u002FV≥1,4 and\u002For eKt\u002FV≥1,2);\n* Dialysis treatment regimen: three sessions per week of at least 4 hours duration;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of active skin disease, cholestasis, severe secondary hyperparathyroidism and other conditions that, in the investigator's opinion, may be responsible for pruritus.\n* Noncompliance of the patient with the protocol (in the investigator's opinion).\n* Use of haemodiafiltration.",{"count":201,"type":20},62,[23],"This randomized controlled trial aims to evaluate the effect of polymethylmethacrylate dialysis membranes use on the intensity of pruritus in patients with CKD stage 5D receiving maintenance hemodialysis.\n\nThe main question it aims to answer is: Does the use of polymethylmethacrylate (PMMA) membranes reduce the intensity of pruritus in dialysis patients?\n\nResearchers will compare PMMA membranes to standard polysulfone-based membranes to see if PMMA works to reduce moderate-to-severe pruritis and pruritis-related quality of life.\n\nParticipants will:\n\n* receive maintenance hemodialysis with PMMA or polysulfone membranes for 2 months;\n* fill in questionnaires about intensity of pruritis and its impact on daily life.",[205,206,207],"CKD (Chronic Kidney Disease) Stage 5D","Hemodialysis","Pruritis",[209,210,211],"polymethylmethacrylate membranes","CKD-associated pruritis","PMMA membranes","2025-03-02",{"date":214,"type":33},"2025-03-04",{"date":216,"type":33},"2025-01-27",{"date":218,"type":20},"2025-10",{"name":39,"class":40},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":103},"100553987","extended-perioperative-administration-of-fibrinolysis-inhibitors-after-cardiac-surgery-100553987","NCT06493227","Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery","The Practice of Routine Extended Perioperative Administration of Fibrinolysis Inhibitors to Reduce the Risk of Bleeding in Cardiac Surgery. Multicenter Prospective Randomized Cluster Crossover Study","PRIORITY","Inclusion Criteria:\n\n1. A hospital that performs a minimum of 250 open heart interventions per year.\n2. Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol).\n\nExclusion Criteria:\n\n* Hospital does not meet inclusion criteria",{"count":229,"type":20},1373,[23],"PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.",[233,234,235],"Thoracic Surgery","Heart Diseases","Fibrinolysis Shutdown","2025-01-22",{"date":216,"type":33},{"date":239,"type":33},"2024-08-01",{"date":241,"type":20},"2026-06-01",{"name":39,"class":40},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":73},"100566378","electrical-cardioversion-as-a-predictor-in-postoperative-preservation-of-sinus-rhythm-100566378","NCT06654401","Electrical Cardioversion As a Predictor in Postoperative Preservation of Sinus Rhythm","Electrical Cardioversion As a Predictor in Postoperative Preservation of Sinus Rhythm in Patients with Persistent Atrial Fibrillation Before Radio Frequency Pulmonary Vein Isolation","Inclusion Criteria:\n\n* Informed consent signed by the patient to participate in the study.\n* Persistent atrial fibrillation resistant to antiarrhythmic drugs for 6 months or more\n* The size of the left atrium is less than 55 mm, volume is less than 130 ml, volume index (LP) is less than 55 ml\u002Fm2\n\nExclusion Criteria:\n\n* Reversible causes of atrial fibrillation (hyperthyroidism, pericarditis, myocarditis).\n* Patients in need of myocardial revascularization and\u002For heart valvular disease correction.\n* Any previous intervention (including MAZE surgery, thoracoscopic ablation; implanted occluder of the auricle of the left atrium.).\n* Patients with severe concomitant pathology requiring correction.\n* Contraindications for administration of anticoagulant therapy.\n* Documented presence of a blood clot in the cavity of the left atrium or other reasons preventing the insertion of catheters into the left atrium.\n* BMI of 40 or more",{"count":251,"type":20},125,[23],"The aim of this study is to evaluate benefits of electric cardioversion in the early and long-term postoperative period in patients after radiofrequency catheter isolation of pulmonary veins. Parameters of the left atrium will be evaluated by transthoracic echocardiography and electroanatomic mapping. Preservation of the sinus rhythm will be assessed by 24-hour electrocardiographic monitoring.\n\nThe main question that is planned to be answered is:\n\nDoes a reverse remodeling of the left atrium and\u002For a decrease in the progression of the fibrosis zone occur after performing electrical cardioversion (and before subsequent catheter ablation) in patients with persistent and long-standing persistent atrial fibrillation (AF)? Can performed electrical cardioversion serve as a predictor of AF freedom in this group of patients?\n\nParticipants will undergo a follow-up examinations (echocardiography, ECG, 24-hour ECG monitoring) at the 3rd, 6th and 12th months after catheter ablation. Based on the results of these examinations, the recurrence rate of AF will be estimated.\n\nTwo groups of patients will include both persistent and long-standing persistent AF. Experimental group will include patients who underwent electrical cardioversion before the intervention, and active comparator group will include those patients who did not undergo it. The experimental group will be subdivided into a persistent AF patients who were successfully cardioverted in sinus rhythm and persistent AF patients who failed to restore sinus rhythm during DC at the time of catheter ablation. Analysis and comparison of subgroups will be performed.",[255,256],"Atrial Fibrillation","Atrial Fibrillation, Persistent",[255,258,259,260,261,262],"Cardioversion","Catheter ablation","Late recurrence","Left atrial voltage","Left atrial volume","2024-12-17",{"date":265,"type":33},"2024-12-20",{"date":267,"type":33},"2024-11-01",{"date":269,"type":20},"2026-01-01",{"name":39,"class":40},{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":291,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":73},"100545096","influence-of-lung-ultrasonography-on-the-prognosis-and-postoperative-outcomes-in-cardiac-surgical-patients-100545096","NCT06377449","Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","Influence of Ultrasound Examination of the Lungs on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","Inclusion Criteria:\n\n* open heart surgery with cardiopulmonary bypass (CPB) between 15 December 2023 and 15 December 2024\n* signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* reoperations on the open heart with CPB\n* surgical procedures on lungs and lung cancer in the anamnesis\n* chronic obstructive pulmonary disease, stage III\n* chronic kidney disease, stages 4 and 5\n* patients with low Risk Score profile by the Society of Thoracic Surgeons",{"count":279,"type":20},186,[23],"The goal of this interventional is to assess advantages of the ultrasound examination of the lungs in the early postoperative period in cardiac surgical patients after heart surgeries requiring cardiopulmonary bypass. Evaluation of pulmonary complications and outcomes during mid-term follow-up, as well as comparison of ultrasound examination and traditional roentgenologic methods (X-ray examination and CT of the chest) will be performed. The main question\\[s\\] it aims to answer are:\n\n* Is ultrasound examination of the lungs a more specific and sensitive method in identification of early postoperative pulmonary complications after on-pump cardiac surgical procedures, in comparison with traditional X-ray methods.\n* Does early identification of interstitial pulmonary edema (based on number of visualised B-lines in the early postoperative period), influences mid-term outcomes in this cohort of patients Participants will undergo ultrasound examination of the lungs on postoperative day 1, 3, 5 and 7 after heart surgery. Based on ultrasound findings and degree of interstitial pulmonary edema, medical (diuretics, anti-inflammatory, e.t.c) therapy will be modified.\n\nResearchers will compare this group of patients with control group, in which ultrasound examination will be performed in the same time frames, but no changes in medical management based on ultrasound findings will be made to see if timely administered medical therapy, based on ultrasound findings, can significantly improve symptoms, hospital lengths of stay and outcomes of this patients.",[283,284,285,286,287,288,289,290],"Ischemic Heart Disease","Aortic Stenosis, Severe","Aortic Insufficiency","Mitral Stenosis","Mitral Insufficiency","Mitral Stenosis With Insufficiency","Tricuspid Insufficiency","Ascending Aortic Aneurysm",[292,293,294,295,296,297],"Ultrasound examination of the lungs","B-lines","Coronary artery bypass grafting","Heart valve surgery","Cardiopulmonary bypass","On-pump cardiac surgery","2024-12-04",{"date":300,"type":33},"2024-12-09",{"date":302,"type":33},"2024-05-15",{"date":269,"type":20},{"name":39,"class":40},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":73},"100554122","the-influence-of-using-vascularized-vaginal-flap-on-the-efficacy-of-mesh-augmented-sacrospinous-hysteropexy-100554122","NCT06494982","The Influence of Using Vascularized Vaginal Flap on the Efficacy of Mesh-augmented Sacrospinous Hysteropexy","The Influence of Augmentation of the Anterior Vaginal Wall With a Vascularized Flap on the Effectiveness of Mesh-augmented Sacrospinous Hysteropexy and Anterior Subfascial Colporrhaphy During Reconstruction of the Pelvic Floor for POP","Inclusion Criteria:\n\n* The subject is a woman with anterior and apical compartment pelvic organ prolapse\n* The age of a subject is 45-80 years\n* Leading point of prolapse is at the level of the hymen or distal to the hymen (Ba, C\\>=1 according to POP-Q classification)\n* The subject gave written consent to participate in the study\n* The subject is able to evaluate the risks of the treatment and make an independent decision on participation in the study\n* The subject is able to fill up validated questionnaires and come to the control visit after the surgery\n\nExclusion Criteria:\n\n* The subject has an active urinary tract infection or skin infection in the region of surgery or acute infectious disease\n* The subject had prior hysterectomy\n* The subject has previously diagnosed or currently active cancer\n* The subject has chronic pelvic pain\n* The subject has cervical elongation\n* The subject has gynecological diseases (recurrent uterine bleeding, endometrial hyperplasia, the presence of atypical cells in cervical smears, adenomyosis, multiple uterine myoma)\n* The subject is planning pregnancy\n* The subject is unable to visit postoperative check-ups\n* Refusal from participation.","45 Years","80 Years",{"count":315,"type":20},60,[23],"This is a prospective randomized controlled trial designed to compare the effectiveness and safety of two methods of pelvic floor reconstruction in patients with pelvic organ prolapse (POP): sacrospinous hysteropexy (SSHP) with synthetic mesh, vascularized anterior vaginal wall flap, anterior colporrhaphy, and sacrospinous hysteropexy with synthetic mesh. , anterior colporrhaphy, as well as the impact of surgery on quality of life.",[319],"Pelvic Organ Prolapse",[321,322,323,324,325],"pelvic organ prolapse","vaginal repair","vaginal mesh","sacrospinous fixation","vaginal flap","2024-07-02",{"date":328,"type":33},"2024-07-10",{"date":330,"type":33},"2024-05-01",{"date":332,"type":20},"2025-10-01",{"name":39,"class":40},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":355,"leadSponsor":356,"locationsCount":73},"100543962","phase-2-study-of-the-rechallenge-concept-in-patients-with-braf-positive-anaplastic-thyroid-cancer-after-progression-on-anti-braf-therapy-100543962","NCT06362694","Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy","Inclusion Criteria:\n\n* immunohistochemically verified anaplastic thyroid cancer;\n* presence of a mutation in the BRAF V600 gene;\n* documented progression during targeted therapy with dabrafenib + trametinib;\n* documented progression during at least one line of chemotherapy (use of taxane-containing chemotherapy is mandatory);\n* age ≥ 18 years;\n* ECOG performance status 0-2;\n* adequate function of internal organs and bone marrow;\n* ability to give written informed consent.\n\nExclusion Criteria:\n\n* primary resistance (absence of initial clinical and radiological response to therapy with dabrafenib and trametinib (response criteria - primary objective response according to RECIST 1.1 criteria and duration of response of at least 3 months);\n* absence of taxane-containing chemotherapy as second or third line;\n* contraindication to taking any of the study drugs (including severe toxicity that occurred during a previous dose, which led to discontinuation of treatment);\n* patients with unsatisfactory functional status (ECOG 3-4);\n* pregnancy and breastfeeding.",{"count":341,"type":20},10,[148],"This pilot phase 2 study evaluates the effectiveness and safety of the Rechallenge concept in patients with BRAF-positive anaplastic thyroid cancer after progression on anti-BRAF therapy. Patients with BRAF-positive anaplastic thyroid cancer who were previously treated with dabrafenib and trametinib (with a clinical or objective response at the start of treatment) and later with tumor progression during anti-BRAF therapy and subsequent lines of chemotherapy are scheduled to undergo targeted therapy (repeated administration of dabrafenib and trametinib in standard doses) and evaluate the outcomes according to the primary and secondary endpoints.",[151],[346,347,348,349,350],"anaplastic thyroid cancer","rechallenge","dabrafenib","trametinib","targeted therapy","2024-04-08",{"date":353,"type":33},"2024-04-12",{"date":162,"type":33},{"date":164,"type":20},{"name":39,"class":40},""]